Skip to content
Home » CPE Launches New Patient Survey on Metastatic Breast Cancer Biomarkers

CPE Launches New Patient Survey on Metastatic Breast Cancer Biomarkers

    Cancer Patients Europe (CPE) is proud to announce the launch of our new patient survey aimed at patients who have been diagnosed with metastatic breast cancer (mBC). This comprehensive survey aims to gather valuable insights into the knowledge and experiences of individuals living with this challenging condition.

    Metastatic breast cancer, particularly in the ER+/HER2- subtype, presents unique challenges and complexities. The ESR1 mutation, a common resistance mutation in mBC, occurs in approximately 1 out of every 2 patients and can significantly impact future treatment decisions. As it is detectable through liquid biopsy (i.e. blood sample), the active diagnostic testing for this mutation can be less invasive than a full tissue biopsy and can also be less expensive.

    To evaluate the current level of awareness about ESR1 and metastatic breast cancer biomarkers, we invite individuals diagnosed with ER+/HER2- mBC to participate in our survey. The input gathered will greatly contribute to improving awareness and outcomes for those affected by this disease.

    The survey is available in multiple languages, including English, French, Italian, Spanish, and German, to ensure accessibility for patients across our five testing countries. We encourage all eligible participants to click on the link below to complete the survey and contribute to advancing research and care in metastatic breast cancer.

    Your voice matters, and together, we can make a difference in the lives of those affected by metastatic breast cancer. Thank you for your participation and support by clicking the buttons below: